AMARIN CORP PLC\UK Payments to Acquire Marketable Securities
AMARIN CORP PLC\UK (AMRN) reported Payments to Acquire Marketable Securities of $90.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-07-29
- AMARIN CORP PLC\UK payments to acquire marketable securities for the quarter ending 2026-06-30 was $39.74M, a 4.89% increase year-over-year.
- AMARIN CORP PLC\UK payments to acquire marketable securities for the quarter ending 2026-03-31 was $50.80M, a 18.31% increase year-over-year.
- AMARIN CORP PLC\UK payments to acquire marketable securities for the quarter ending 2025-12-31 was $50.52M, a 27.67% decline year-over-year.
- AMARIN CORP PLC\UK payments to acquire marketable securities for the quarter ending 2025-09-30 was $69.13M, a 36.78% decline year-over-year.
- AMARIN CORP PLC\UK payments to acquire marketable securities for fiscal 2025 was $200.47M, a 28.09% decline from fiscal 2024.
- AMARIN CORP PLC\UK payments to acquire marketable securities for fiscal 2024 was $278.78M, a 29.60% increase from fiscal 2023.
- AMARIN CORP PLC\UK payments to acquire marketable securities for fiscal 2023 was $215.10M, a 163.49% increase from fiscal 2022.
- AMARIN CORP PLC\UK payments to acquire marketable securities for fiscal 2022 was $81.63M, a 71.87% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $90.54M 10-Q · filed 2026-07-29 | $141.06M derived: sum of 3 quarters · filed 2026-07-29 | $210.19M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $50.80M 10-Q · filed 2026-04-29 | $101.31M derived: sum of 2 quarters · filed 2026-04-29 | $170.44M derived: sum of 3 quarters · filed 2026-04-29 | $208.33M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $50.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $119.65M derived: sum of 2 quarters · filed 2026-03-02 | $157.54M derived: sum of 3 quarters · filed 2026-07-29 | $200.47M 10-K · filed 2026-03-02 |
| 2025-09-30 | $69.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $107.02M derived: sum of 2 quarters · filed 2026-07-29 | $149.96M 10-Q · filed 2025-10-29 | $219.79M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $37.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $80.83M 10-Q · filed 2026-07-29 | $150.66M derived: sum of 3 quarters · filed 2026-07-29 | $260.02M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $42.94M 10-Q · filed 2026-04-29 | $112.78M derived: sum of 2 quarters · filed 2026-04-29 | $222.13M derived: sum of 3 quarters · filed 2026-04-29 | $288.43M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $69.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $179.19M derived: sum of 2 quarters · filed 2026-03-02 | $245.50M derived: sum of 3 quarters · filed 2026-03-02 | $278.78M 10-K · filed 2026-03-02 |
| 2024-09-30 | $109.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $175.66M derived: sum of 2 quarters · filed 2025-10-29 | $208.94M 10-Q · filed 2025-10-29 | $308.54M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $66.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $99.59M 10-Q · filed 2025-07-30 | $199.19M derived: sum of 3 quarters · filed 2026-03-02 | $232.42M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $33.28M 10-Q · filed 2025-05-07 | $132.88M derived: sum of 2 quarters · filed 2026-03-02 | $166.12M derived: sum of 3 quarters · filed 2026-03-02 | $195.85M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $99.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $132.84M derived: sum of 2 quarters · filed 2026-03-02 | $162.57M derived: sum of 3 quarters · filed 2026-03-02 | $215.10M 10-K · filed 2026-03-02 |
| 2023-09-30 | $33.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $62.97M derived: sum of 2 quarters · filed 2024-10-30 | $115.50M 10-Q · filed 2024-10-30 | $159.62M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-06-30 | $29.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $82.26M 10-Q · filed 2024-07-31 | $126.39M derived: sum of 3 quarters · filed 2025-03-12 | $149.72M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-03-31 | $52.52M 10-Q · filed 2024-05-01 | $96.65M derived: sum of 2 quarters · filed 2025-03-12 | $119.98M derived: sum of 3 quarters · filed 2025-03-12 | $119.98M derived: sum of 4 quarters · filed 2025-03-12 |
| 2022-12-31 | $44.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $67.46M derived: sum of 2 quarters · filed 2025-03-12 | $67.46M derived: sum of 3 quarters · filed 2025-03-12 | $81.63M 10-K · filed 2025-03-12 |
| 2022-09-30 | $23.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $23.34M derived: sum of 2 quarters · filed 2023-11-01 | $37.51M 10-Q · filed 2023-11-01 | $94.64M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $14.17M 10-Q · filed 2023-08-02 | $71.30M derived: sum of 3 quarters · filed 2024-02-29 | $229.86M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $14.17M 10-Q · filed 2023-05-03 | $71.30M derived: sum of 2 quarters · filed 2024-02-29 | $229.86M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | $57.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $215.69M derived: sum of 2 quarters · filed 2024-02-29 | $290.19M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $158.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $233.07M 10-Q · filed 2022-10-27 | ||
| 2021-06-30 | $74.51M 10-Q · filed 2022-08-03 | |||
| 2020-12-31 | $91.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $151.22M derived: sum of 2 quarters · filed 2023-03-01 | $368.05M derived: sum of 3 quarters · filed 2023-03-01 | $678.70M 10-K · filed 2023-03-01 |
| 2020-09-30 | $59.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $276.46M derived: sum of 2 quarters · filed 2021-11-03 | $587.11M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $216.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $527.48M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $310.65M 10-Q · filed 2021-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |